Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed cutaneous T-cell lymphoma
• * Stage IB-IV disease
• Measurable disease
• Newly diagnosed or previously treated disease
• * No demonstrated resistance to prior bexarotene
• PATIENT CHARACTERISTICS:
• Performance status
• Karnofsky 60-100%
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hepatic
• AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• Bilirubin \< 1.5 times ULN
• Renal
• Creatinine ≤ 1.5 times ULN
• Cardiovascular
• Ejection fraction ≥ 50% by MUGA or 2-D echocardiogram
• No New York Heart Association class II-IV heart disease
• No clinical evidence of congestive heart failure
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 4 weeks after completion of study treatment
• No history of hypersensitivity reactions attributed to doxorubicin HCl liposome or its components
• No active potentially life-threatening infection
• No other acute disease
• PRIOR CONCURRENT THERAPY:
• Chemotherapy
• See Disease Characteristics
• Prior doxorubicin allowed provided the cumulative dose is ≤ 300 mg/m\^2
• Prior epirubicin hydrochloride allowed provided the cumulative dose is ≤ 540 mg/m\^2